Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings.
The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies.
Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.
On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the Eastern District of Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 30, 23 | -0.30 Increased by +98.86% | -0.53 Increased by +43.40% |
| Aug 16, 23 | -1.52 Increased by +96.38% | -2.04 Increased by +25.49% |
| May 12, 23 | -3.91 Increased by +96.92% | 5.75 Decreased by -168.00% |
| Feb 23, 23 | -12.33 Decreased by -103.07% | -9.76 Decreased by -26.33% |
| Nov 8, 22 | -26.40 Increased by +90.57% | -21.20 Decreased by -24.53% |
| Aug 11, 22 | -42.00 Increased by +86.96% | -50.80 Increased by +17.32% |
| May 4, 22 | -126.80 Increased by +66.46% | -74.00 Decreased by -71.35% |
| Mar 16, 22 | 401.20 Increased by +152.10% | 59.00 Increased by +580.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by -100.00% | -1.93 M Increased by +93.38% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 30.00 K Decreased by -90.00% | -7.38 M Increased by +2.07% | Decreased by -24.58 K% Decreased by -879.29% |
| Mar 31, 23 | -14.00 K Decreased by -103.32% | 11.40 M Increased by +189.03% | Decreased by -81.46 K% Decreased by -2.58 K% |
| Dec 31, 22 | 310.00 K Decreased by -22.50% | -9.25 M Decreased by -131.42% | Decreased by -2.98 K% Decreased by -140.55% |
| Sep 30, 22 | 238.00 K Decreased by -15.30% | -29.20 M Decreased by -72.18% | Decreased by -12.27 K% Decreased by -103.29% |
| Jun 30, 22 | 300.00 K Increased by +49.25% | -7.53 M Increased by +50.87% | Decreased by -2.51 K% Increased by +67.08% |
| Mar 31, 22 | 422.00 K Increased by +113.13% | -12.81 M Increased by +24.26% | Decreased by -3.04 K% Increased by +64.46% |
| Dec 31, 21 | 400.00 K Increased by +426.32% | 29.43 M Increased by +272.71% | Increased by +7.36 K% Increased by +132.82% |